Bivalirudin.

Bivalirudin. Research Abstract Details

Research Abstract Table of Contents

Jump to the:

Abstract Text of This Paper

Journal Published

MeSH Keywords of This Abstract

Chemicals and Substances Used in this Paper

Grants and Granting Agency of this Research

Database Accession Numbers Used in this Paper

Bivalirudin. Abstract Text:

Bivalirudin is a direct thrombin inhibitor (DTI) frequently used for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention (PCI). Bivalirudin has a unique pharmacologic profile: unlike other marketed DTIs, it undergoes predominant non-organ elimination (proteolysis), and has the shortest half-life ( approximately 25 min). Its affinity for thrombin is intermediate between that of lepirudin (highest) and argatroban (lowest) - this helps explain why it interferes with functional clotting assays to an extent intermediate between that achieved by these two other DTIs. This effect is best known for the PT (INR) - higher affinity for thrombin corresponds to lower molar DTI requirements to prolong the APTT; in turn, lower concentrations required for APTT prolongation (and, presumably, in-vivo effect) result in reduced PT (INR) prolongation. Bivalirudin is primarily used for its first FDA-approved indication, namely anticoagulation during percutaneous transluminal coronary angioplasty ("balloon angioplasty"), the most frequent type of PCI. Bivalirudin is also indicated for PCI with provisional use of glycoprotein IIb/IIIa antagonist therapy, and for patients with, or at risk of, heparin-induced thrombocytopenia (HIT), or HIT with thrombosis syndrome (HITTS), undergoing PCI. The bivalirudin development program has used a "quadruple" endpoint comprising a "triple" efficacy endpoint plus major bleeding - this approach anticipated the subsequent emphasis on strategies to improve clinical outcomes through bleeding reduction. Besides summarizing the key trials evaluating bivalirudin use for acute coronary syndrome (especially employing PCI), we review also the studies of bivalirudin as anticoagulant for "on-" and "off-pump" cardiac surgery, including both HIT and non-HIT situations.

Bivalirudin. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Bivalirudin. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Thrombosis and haemostasis

VOLUME: 99

Page Numbers: 830-9

Journal Abbreviation: Thromb. Haemost.

ISSN: 0340-6245

DAY: 1

MONTH: May

YEAR: 2008

Bivalirudin. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7608063

Bivalirudin. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Bivalirudin. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Bivalirudin.

AFFILIATION: Hamilton Regional Laboratory Medicine Program, Room 1-180A, Hamilton Health Sciences (Hamilton General Site), 237 Barton St. E., Hamilton, Ontario, L8L 2X2 Canada. E-mail: twarken@mcmaster.ca.

Country: Germany